Igg2a isotype clone 2a3

CD73^−/− mice were intraperitoneally administered 300 μg of anti‐Ly6G antibody (clone1A8, BioXCell, West Lebanon, NH) at Day ‐2, 0, and 1 day after the last caerulein injection. IgG2a isotype (clone 2A3, BioXCell, West Lebanon, NH) was used for control. Mice were euthanized at Day 4.

All animal experiments were approved by the Institutional Animal Care and Use Committee of the National Taiwan University College of Medicine (Taipei, Taiwan; no. 20200014). Five‐week‐old female mice were obtained from the National Laboratory Animal Center, Taipei, Taiwan. For orthotopic models, SCA9 (5 × 10⁵) and MTC‐Q1 cells (1 × 10⁶) were injected into the tongues of Swiss Webster and C57BL/6 mice, respectively. For the subcutaneous model, MTC‐Q1 cells (2 × 10⁶) were injected subcutaneously into the flanks of C57BL/6 mice. Mice were sacrificed when the tumor volume exceeded 20 mm or the body weight was reduced by ≥ 20%. To evaluate the effect of itraconazole and anti‐PD‐1 antibody treatment on tumor growth in a subcutaneous model, itraconazole (600 μg/mouse, Sigma Aldrich, St. Louis, MO, USA) or the solvent control was administered intraperitoneally every day. The IgG2a isotype (clone 2A3) and anti‐PD‐1 (clone RMP1‐14) controls were obtained from Bio X Cell (Lebanon, NH, USA) and intraperitoneally injected twice a week (300 μg/mouse).